152 related articles for article (PubMed ID: 31455846)
1. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.
Herlemann A; Huang HC; Alam R; Tosoian JJ; Kim HL; Klein EA; Simko JP; Chan JM; Lane BR; Davis JW; Davicioni E; Feng FY; McCue P; Kim H; Den RB; Bismar TA; Carroll PR; Cooperberg MR
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):136-143. PubMed ID: 31455846
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
[TBL] [Abstract][Full Text] [Related]
3. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
4. Identifying intermediate-risk candidates for active surveillance of prostate cancer.
Savdie R; Aning J; So AI; Black PC; Gleave ME; Goldenberg SL
Urol Oncol; 2017 Oct; 35(10):605.e1-605.e8. PubMed ID: 28736249
[TBL] [Abstract][Full Text] [Related]
5. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
6. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
7. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
9. Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance.
Leapman MS; Ameli N; Cooperberg MR; Chu C; Hussein A; Shinohara K; Carroll PR
Eur Urol; 2017 Sep; 72(3):329-332. PubMed ID: 27157998
[TBL] [Abstract][Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
12. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
13. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
14. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
15. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
[TBL] [Abstract][Full Text] [Related]
16. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
17. A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI.
Li L; Shiradkar R; Leo P; Algohary A; Fu P; Tirumani SH; Mahran A; Buzzy C; Obmann VC; Mansoori B; El-Fahmawi A; Shahait M; Tewari A; Magi-Galluzzi C; Lee D; Lal P; Ponsky L; Klein E; Purysko AS; Madabhushi A
EBioMedicine; 2021 Jan; 63():103163. PubMed ID: 33321450
[TBL] [Abstract][Full Text] [Related]
18. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
19. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
20. Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings.
Lantz A; Falagario UG; Ratnani P; Jambor I; Dovey Z; Martini A; Lewis S; Lundon D; Nair S; Phillip D; Haines K; Cormio L; Carrieri G; Kryprianou N; Tewari A
Eur Urol Oncol; 2022 Apr; 5(2):187-194. PubMed ID: 32891599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]